Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M

Kyle LaHucik

Senior Reporter

Gene editing company Metagenomi has set a price range for its proposed initial public offering, marking a key step for preclinical biotechs after weeks of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

Exclusive: Infectious disease doctors consider 'mini-ACIP' if RFK erodes CDC vaccine panel

BridgeBio oncology spinout to go public via combination with SPAC from Cormorant and Bihua Chen

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

Pfizer vet William Pao’s next venture; Sanofi’s computational science exec leaves

How AI can address ongoing challenges in the life sciences industry

Gene edit­ing start­up Metageno­mi fi­nal­ly sets IPO range, as pre­clin­i­cal biotech eyes $87M

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M